Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Research & Drug Development

Partners

Agreement with Merck Serono

In 2006, Newron signed an agreement with Merck Serono giving them exclusive worldwide rights to develop, manufacture and commercialise safinamide in Parkinson's disease (PD), Alzheimer's disease, and other therapeutic applications.  For more details, see Media, Press Releases. 

HF0420

The rights to HF0420, a low molecular weight heparin product with potential use in the treatment of certain CNS diseases, in 2009 were returned to its inventor, Professor Umberto Cornelli, Professor of Pharmacology at Loyola University Medical Center Chicago, who will pursue clinical development of HF0420 with the co-inventors from Loyola University. They intend to conduct further research into indications including dementia and Alzheimer's disease.  In return, Newron shall receive undisclosed milestone payments and royalties on the successful development and commercialization of the compound in any indication. For more details, see Media, Press Releases.